SNMMI 2022 Meeting
In-depth coverage of the SNMMI 2022 Meeting
Piflufolastat F 18 is a radiopharmaceutical that targets the prostate-specific membrane antigen during imaging.
This model assigns workers to additional or alternate roles that match existing skills and providing proper re-training.
Researchers retrospectively analyzed patients who had received both 68Ga-PSMA PET/CT and mpMRI testing.
The approach may help inform clinical decision-making early in treatment.
Updates may be needed to guidelines for salvage radiation treatments in patients with local recurrence of prostate cancer.
Developers and users must be aware of the potential for data attacks and manipulation when considering AI models for imaging.
The authors of the study won the 2022 SNMMI Abstract of the Year Award.
The novel artificial intelligence can produce high-quality PET/CT images while decreasing radiation exposure to patients.
Researchers conducted a prospective phase 2 imaging study to compare PSMA and GRP-R-targeted imaging during initial staging.
Guided imagery can enhance coping, reduce anxiety, and decrease heart rate, respirations, and blood pressure.
A study explore values of parametric Ki imaging in total-body 68Ga-PSMA-11 PET/CT in patients with prostate cancer.
The framework emphasizes the importance of establishing trust among stakeholders.
The study is the first to show that lingering COVID-19 symptoms can be attributed to ongoing lung inflammation.
During an SNMMI Annual Meeting scientific session, researchers discussed imaging modalities to diagnose different cancers.
Advertisement
Advertisement
